Exiqon Licenses LNA Technology to Idexx Labs for Veterinary Dx | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exiqon today announced it has issued a non-exclusive license to Idexx Laboratories for its LNA (locked nucleic acid) technology for veterinary disease diagnostic products.

The deal provides Exiqon with upfront and milestone payments, as well as royalty payments on global sales of products covered by the agreement. Further financial details were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.